Their main advantages and remaining gaps relative to conventional IgG4 PD-1/PD-L1 mAbs together with those of checkpoint-targeting bispecific and conjugate or tumor-restricted PD-1/PD-L1 formats discussed below, are summarized in Table 1. The gene discussed is PDCD1; the disease is neoplasm.